This study aimed to investigate the correlation between miRNA-216b expression in patients with non-small cell lung cancer (NSCLC) and 18F-fluorodeoxyglucose (FDG) uptake by PET/CT and to explore the clinical application value of 18F-FDG PET/CT in miRNA-216b based on therapy for NSCLC. Eighty patients with NSCLC and 40 healthy subjects were enrolled in our study. The SUVmax of the lesion area by PET/CT imaging was calculated. SUVmax represented the highest concentration of 18F-FDG in the lesion. The expression of miRNA-216b in the plasma and fiber bronchoscopic puncture of NSCLC patients was detected by RT qPCR. Then Pearson correlation analysis was used to analyze the correlation between miRNA-216b expression and 18F-FDG uptake in patients with different types of NSCLC. Compared with healthy subjects, SUVmax of early adenocarcinoma and advanced adenocarcinoma were increased. Compared with healthy subjects, SUVmax of early squamous and advanced squamous were increased. And the SUVmax content of advanced adenocarcinoma and squamous cell carcinoma was higher than that of early adenocarcinoma and squamous cell carcinoma. Compared with healthy subjects, the expression of miRNA-216b in the plasma of patients with early and advanced adenocarcinoma was reduced, and the expression of miRNA-216b in the plasma of patients with early and advanced squamous cell carcinoma was reduced. Compared with adjacent tissues, the expression of miRNA-216b in early adenocarcinoma tissues and advanced adenocarcinoma tissues was reduced, and the expression in early squamous cell carcinoma and advanced squamous cell carcinoma was reduced. Pearson correlation analysis showed a negative correlation between SUVmax and miRNA-216b (plasma and tissue) in patients with four types of NSCLC. miRNA-216b expression was negatively correlated with 18F-FDG uptake in NSCLC. miRNA-216b could be used for the classification and staging of non-small cell lung cancer. 18F-FDG PET/CT may be used to evaluate the therapeutic response in application of miRNA-216b-based cancer treatment.

中文翻译：

---

miRNA-216b 的表达与非小细胞肺癌中 18F-FDG 的摄取呈负相关

本研究旨在探讨非小细胞肺癌（NSCLC）患者miRNA-216b表达与PET/CT摄取18F-氟脱氧葡萄糖（FDG）的相关性，探讨18F-FDG PET/CT的临床应用价值。在 miRNA-216b 中基于 NSCLC 的治疗。我们的研究招募了 80 名 NSCLC 患者和 40 名健康受试者。通过PET/CT成像计算病变区域的SUVmax。SUVmax 代表病灶中 18F-FDG 的最高浓度。RT qPCR检测NSCLC患者血浆和纤维支气管镜穿刺中miRNA-216b的表达。然后采用Pearson相关分析分析不同类型NSCLC患者miRNA-216b表达与18F-FDG摄取的相关性。与健康人相比，早期腺癌和晚期腺癌的SUVmax升高。与健康受试者相比，早期鳞状上皮和晚期鳞状上皮的SUVmax增加。晚期腺癌和鳞状细胞癌的SUVmax含量高于早期腺癌和鳞状细胞癌。与健康人相比，早期和晚期腺癌患者血浆中miRNA-216b的表达降低，早期和晚期鳞状细胞癌患者血浆中miRNA-216b的表达降低。与癌旁组织相比，miRNA-216b在早期腺癌组织和晚期腺癌组织中的表达降低，在早期鳞状细胞癌和晚期鳞状细胞癌中的表达降低。Pearson 相关分析显示，四种类型 NSCLC 患者的 SUVmax 与 miRNA-216b（血浆和组织）呈负相关。miRNA-216b 表达与 NSCLC 中 18F-FDG 的摄取呈负相关。miRNA-216b可用于非小细胞肺癌的分类和分期。18F-FDG PET/CT 可用于评估基于 miRNA-216b 的癌症治疗应用中的治疗反应。